|
private:progenindustriesltd
|
56710
|
May 31st, 2019 12:00AM
|
Progen Pharmaceuticals
|
310
|
13.00
|
Open
|
Pharmaceuticals
|
May 31st, 2019 02:59AM
|
May 31st, 2019 02:59AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
Open
|
biotechnology, drug development
|
Open
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 17th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 16th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 15th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 14th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 13th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 12th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 11th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 10th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|
|
private:progenindustriesltd
|
56710
|
Feb 9th, 2018 12:00AM
|
Progen Pharmaceuticals
|
274
|
16.00
|
Open
|
Pharmaceuticals
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.
Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.
|
|
|
|
|
|
|
|
|
|
Progen Industries Ltd
|
|
Pharmaceuticals & Biotechnology
|